21:17 , Jun 20, 2019 |  BC Innovations  |  Emerging Company Profile

Casma: Tailoring autophagy targets to indications

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases. According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
18:57 , May 4, 2018 |  BC Week In Review  |  Financial News

Casma brings in $58.5M from Third Rock

Casma Therapeutics Inc. (Cambridge, Mass.) debuted on May 3 with a tranched $58.5 million series A round from Third Rock Ventures (see BioCentury, May 3) . Casma’s therapeutics induce autophagy to treat inflammatory, neurodegenerative, muscular...
10:05 , May 3, 2018 |  BC Extra  |  Financial News

Third Rock funnels $58.5M into autophagy newco Casma

Casma Therapeutics Inc. (Cambridge, Mass.) debuted on Thursday with a tranched $58.5 million series A round from Third Rock Ventures ( see BioCentury, May 3 ). Casma’s therapeutics induce autophagy to treat inflammatory, neurodegenerative, muscular...
10:02 , May 3, 2018 |  BioCentury  |  Finance

Rock the Casma

The recent discovery of autophagy-inducing targets led Third Rock Ventures to launch Casma Therapeutics Inc. with a $58.5 million series A to develop therapeutics that promote autophagy and ameliorate cellular distress in inflammatory, neurodegenerative, muscular...